RxDoctor Payments Data

Carmen Cawley, MD

Internal Medicine · San Antonio, TXNPI 1801903885

Payments from drug & device makers

$7,610in general payments, 2019–2025

Across 400 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$945
  • AbbVie$887
  • AstraZeneca$828
  • Novo Nordisk$512
  • Kowa Pharmaceuticals America, Inc.$456
  • Amgen$411
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,54599%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,610 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$227,761
Medicare patients
284
Services billed
7,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide67$79,148
OzempicSemaglutide36$61,119
EliquisApixaban55$54,375
Synjardy XrEmpagliflozin/Metformin Hcl36$33,276
CreonLipase/Protease/Amylase24$31,099
JardianceEmpagliflozin33$25,631
MounjaroTirzepatide14$22,160
RybelsusSemaglutide18$21,209
Tresiba Flextouch U-100Insulin Degludec24$20,416
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$17,515
Repatha SyringeEvolocumab20$15,111
Repatha SureclickEvolocumab13$11,442
Xigduo XrDapaglifloz Propaned/Metformin13$10,970
VascepaIcosapent Ethyl15$8,318
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$945$101,30881 claims
Novo NordiskOzempic, Rybelsus$512$82,32854 claims
PfizerEliquis, Levoxyl$378$59,957171 claims
Boehringer IngelheimSynjardy Xr, Jardiance$209$58,90769 claims
AbbVieCreon, Synthroid$887$35,51281 claims
AstraZenecaBreztri Aerosphere$828$17,51517 claims
GSKTrelegy Ellipta$194$7,53712 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$3,130216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →